CooperCompanies Q2 Revenue Rises 8% to $1.082B, Non-GAAP EPS Up 26%
COO•CooperCompanies delivered Q2 revenue of $1.082 billion, up 8% (5% organic), and non-GAAP EPS of $1.21, a 26% increase. The quarter included a $271.6 million litigation charge that drove GAAP EPS to $(0.40) and the company raised fiscal 2026 revenue guidance to $4.285–$4.321 billion.
1. Q2 Financial Results
CooperCompanies reported Q2 revenue of $1.082 billion, an 8% year-over-year increase (5% organic). GAAP diluted EPS was $(0.40), down $0.84 due to a litigation-related charge, while non-GAAP diluted EPS rose 26% to $1.21, marking the tenth consecutive quarter of consensus-beating performance.
2. CooperVision Segment Performance
CooperVision delivered $723.5 million in revenue, up 8% (4% organic). Toric and multifocal lenses grew 11% reported (7% organic), sphere and other lenses rose 5% (1% organic), with Americas up 7%, EMEA up 6%, and Asia Pacific down 6% year-over-year.
3. CooperSurgical Segment Performance
CooperSurgical generated $358.0 million in revenue, up 8% reported and 6% organic. Office and surgical products increased 4%, while fertility business sales jumped 13% reported (10% organic), reflecting strong demand for embryo culture media.
4. Litigation Charge and Guidance Update
The company recorded a $271.6 million pre-tax SG&A charge for recall-related litigation, partially offset by $52.5 million in insurance recoveries. It repurchased $13.1 million of stock and raised fiscal 2026 revenue guidance to $4.285–$4.321 billion, non-GAAP EPS to $4.58–$4.66 and reaffirmed free cash flow targets above $2.2 billion.
